---
title: "Hibsago (bepirovirsen) in Chronic hepatitis B virus infection in adults without cirrhosis: Effect on quality measures"
description: "Formulary evidence on Hibsago (bepirovirsen, GSK3228836) in Chronic hepatitis B virus infection in adults without cirrhosis: Effect on quality measures. Topics: Medicaid Adult Core Set: Evaluation of Hepatitis B and C measure added for 2027; Evaluation of Hepatitis B and C measure: listing in the 2027 Adult Core Set; Evaluation of Hepatitis B and C measure: reported rates, populations, and testing results; Viral hepatitis quality measures with a hepatitis B component in federal and commercial programs; 4 further topics. 8 evidence topics quoted from 8 sources."
canonical: "https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/product-information-and-disease-description/effect-on-quality-measures"
published: "2026-10-21T22:39:04-04:00"
modified: "2026-10-22T19:07:03-04:00"
---
# Hibsago (bepirovirsen) in Chronic hepatitis B virus infection in adults without cirrhosis: Effect on quality measures
## 2.1.2.13 Effect of Bepirovirsen on Quality Measures
### Medicaid Adult Core Set: Evaluation of Hepatitis B and C measure added for 2027
> “The following measures are being added to the 2027 Adult Core Set for voluntary state reporting”
> “This measure assesses the number and percentage of adult, non-dually eligible Medicaid beneficiaries who were tested for hepatitis B, tested for hepatitis C, and treated for hepatitis C. Timely testing, diagnosis, and treatment of hepatitis can prevent serious liver damage and improve outcomes.”
> “Measure Steward: Medicaid Outcomes Distributed Research Network’s (MODRN) Data Coordinating Center at the University of Pittsburgh”
Source: [CMS (2025)](https://www.medicaid.gov/federal-policy-guidance/downloads/sho25005.pdf)
### Evaluation of Hepatitis B and C measure: listing in the 2027 Adult Core Set
| Field | 2027 Adult Core Set |
| --- | --- |
| Reporting category | “2027 Voluntary Adult Core Set Measures” |
| Domain | “Primary Care Access and Preventive Care” |
| CMIT number | “1852” |
| Measure steward | “MODRN” |
| Measure name | “Evaluation of Hepatitis B and C (EHBC-AD)” |
| Data collection method | “Administrative” |
| Status | “This measure was added to the 2027 Adult Core Set.” |
Source: [CMS 2027 Adult Core Set](https://www.medicaid.gov/medicaid/quality-of-care/downloads/2027-adult-core-set.pdf)
### Evaluation of Hepatitis B and C measure: reported rates, populations, and testing results
> “Nine rates are reported for this measure across three populations: all adults, adults diagnosed with opioid use disorder (OUD), and pregnant women.”
> “The individual who suggested this measure said it is not currently in use by any state Medicaid or CHIP programs but was tested in seven state Medicaid programs”
> “They noted that measure testing results showed that hepatitis screening and treatment rates are low”
> “a Workgroup member said this is a testing measure rather than a screening measure and is not intended to capture everyone. They added that hepatitis B testing rates were low across states where the measure was tested, highlighting an opportunity to develop targeted testing strategies.”
Source: [Mathematica (2025)](https://www.mathematica.org/-/media/internet/features/2025/child-and-adult-core-set/2027coresetreview-finalreport_updated.pdf)
### Viral hepatitis quality measures with a hepatitis B component in federal and commercial programs
| Measure | Brief description | Identifier | Steward | Programs using the measure |
| --- | --- | --- | --- | --- |
| Evaluation of Hepatitis B and C (EHBC-AD) | “Assess the number and percentage of adult, non-dually eligible Medicaid beneficiaries who were tested for hepatitis B, tested for hepatitis C, and treated for hepatitis C.” | “CMIT: 1852” | “MODRN” | “Medicaid Adult Core Set (2027)” |
| Adult Immunization Status | “Percentage of patients 19 years of age and older who are up-to-date on recommended routine vaccines for influenza; tetanus and diphtheria (Td) or tetanus, diphtheria and acellular pertussis (Tdap); zoster; pneumococcal; and hepatitis B.” | “MIPS: 493” “CMIT: 26” | “NCQA” | “MIPS Program” “Medicaid Adult Core Set” “HEDIS” “QHP QRS” |
Source: [CDC guidelines and quality measures (2026)](https://www.cdc.gov/high-quality-care/hcp/guidelines-quality-measures.html)
### Healthy People 2030 objective IID-13: awareness of chronic hepatitis B infection
| Field | Objective record |
| --- | --- |
| Objective | “Increase the proportion of persons aware they have chronic hepatitis B” |
| National baseline | “32.4 percent of persons with chronic hepatitis B were aware they have chronic hepatitis B in 2013-16” |
| National target | “90.0 percent” |
| National status | “Baseline only” |
| Data source | “National Health and Nutrition Examination Survey (NHANES), CDC/NCHS” |
Source: [ODPHP Healthy People 2030 IID-13](https://odphp.health.gov/healthypeople/objectives-and-data/browse-objectives/infectious-disease/increase-proportion-people-who-know-they-have-chronic-hepatitis-b-iid-13)
### Healthy People 2030 objective IID-15: deaths with hepatitis B as a cause
| Field | Objective record |
| --- | --- |
| Objective | “Reduce the rate of deaths with hepatitis B as the underlying or a contributing cause” |
| National baseline | “0.46 deaths with hepatitis B as the underlying or contributing cause of death per 100,000 population were reported in 2017” |
| Most recent data | “0.40 deaths with hepatitis B as the underlying or contributing cause of death per 100,000 population (2024)” |
| National target | “0.16 per 100,000” |
| National status | “Improving” |
Source: [ODPHP Healthy People 2030 IID-15](https://odphp.health.gov/healthypeople/objectives-and-data/browse-objectives/infectious-disease/reduce-rate-deaths-hepatitis-b-cause-iid-15)
### Viral Hepatitis National Strategic Plan: hepatitis B core indicators and targets
| Core indicator | Measure | Baseline | 2025 target | 2030 target |
| --- | --- | --- | --- | --- |
| “Reduce acute hepatitis B infections” | “Estimated number of cases” | “22,200” | “18,000” | “2,200” |
| “Increase proportion of people with hepatitis B infection aware of their infection” | “Rate/100,000” | “32 (2013–2016 baseline)” | “50” | “90” |
| “Reduce rate of hepatitis B–related deaths” | “Rate/100,000” | “0.46” | “0.37” | “0.16” |
Source: [HHS Viral Hepatitis National Strategic Plan (2020)](https://www.hhs.gov/sites/default/files/Viral-Hepatitis-National-Strategic-Plan-2021-2025.pdf)
### CDC universal hepatitis B screening recommendation and national awareness goal
> “HBV screening at least once during a lifetime for adults aged ≥18 years (new recommendation)”
> “calls for an increase in the proportion of persons with HBV infection who are aware of their infection from 32% (2013–2016) to 90% by 2030”
Source: [Conners et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9997714/)
### Product-specific effect on quality measures
No evidence found.
## Related pages
- [Hibsago (bepirovirsen): Chronic hepatitis B virus infection in adults without cirrhosis](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis) · [Markdown](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis.md)
- [Hibsago (bepirovirsen) in Chronic hepatitis B virus infection in adults without cirrhosis: Terms and abbreviations](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/terms-and-abbreviations.md)
- [Hibsago (bepirovirsen): Chronic hepatitis B virus infection in adults without cirrhosis](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/executive-summary.md)
- [Hibsago (bepirovirsen) in Chronic hepatitis B virus infection in adults without cirrhosis: Product information and disease description](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/product-information-and-disease-description.md)
- [Hibsago (bepirovirsen) in Chronic hepatitis B virus infection in adults without cirrhosis: Clinical evidence](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/clinical-evidence.md)
- [Hibsago (bepirovirsen) in Chronic hepatitis B virus infection in adults without cirrhosis: Economic information and modeling report](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/economics) · [Markdown](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/economics.md)
- [Hibsago (bepirovirsen) in Chronic hepatitis B virus infection in adults without cirrhosis: References](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/references) · [Markdown](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/references.md)
- [Hibsago (bepirovirsen) in Chronic hepatitis B virus infection in adults without cirrhosis: new drug review](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/monograph/review) · [Markdown](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/monograph/review.md)
- [Hibsago (bepirovirsen) in Chronic hepatitis B virus infection in adults without cirrhosis: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/cost-effectiveness-analyses.md)